<DOC>
	<DOCNO>NCT02288559</DOCNO>
	<brief_summary>This multicenter , randomize , single-masked , sham injection-controlled study investigate exposure-response safety lampalizumab administer intravitreally every 2 week ( Q2W ) every 4 week ( Q4W ) 24 week participant geographic atrophy ( GA ) secondary age-related macular degeneration ( AMD ) . The anticipated time study treatment 24 week . The target sample size approximately 90 participant .</brief_summary>
	<brief_title>A Study Lampalizumab Intravitreal Injections Administered Every Two Weeks Every Four Weeks Participants With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Willingness provide sign Informed Consent Health Insurance Portability Accountability Act authorization Participants age great equal ( &gt; /= ) 60 year welldemarcated area GA secondary AMD absence choroidal neovascularization study eye Women child bear potential men remain abstinent use contraceptive method Ability willingness undertake schedule visit assessment History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation study eye Prior treatment externalbeam radiation therapy transpupillary thermotherapy study eye Previous intravitreal drug administration study eye . A single intraoperative administration corticosteroid cataract surgery least 3 month prior screen permit Previous cellbased intraocular treatment study eye Intraocular surgery study eye Uncontrolled glaucoma history glaucomafiltering surgery study eye History corneal transplant study eye GA either eye due cause AMD Proliferative diabetic retinopathy either eye Active history neovascular ( wet ) AMD either eye History idiopathic autoimmuneassociated uveitis , ocular intraocular condition , infectious inflammatory ocular disease Active uveitis infectious conjunctivitis , keratitis , scleritis endophthalmitis Previous systemic treatment complement inhibitor inhibitors/modulators visual cycle Previous expression vector mediate intraocular treatment Uncontrolled blood pressure atrial fibrillation Medical condition associate clinically significant risk bleed Predisposition history increase risk infection Active malignancy within previous 12 month except appropriately treat carcinoma situ cervix , resolve nonmelanoma skin carcinoma , prostate cancer Gleason score less equal 6 , stable prostatespecific antigen &gt; /= 12 month History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lampalizumab injection Women child bear potential must negative serum pregnancy test within 28 day prior initiation study treatment Previous participation study investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>